参考文献/References:
[1].Lai YC,Potoka KC,Champion HC,et al. Pulmonary arterial hypertension: the clinical syndrome[J].Circ Res,2014,115(1):115-130.
[2].Dodson MW,Brown LM,Gregory EC.Pulmonary arterial hypertension[J].Heart Fail Clin, 2018,14(3):255-269.
[3].[3] Daniel C,Gerlach K,Martin V,et al. Nuclear factor of activated T cells-A transcription factor family as critical regulator in lung and colon cancer[J]. Int J Cancer,2014,134(8):1767-1775.
[4].[4] Shou J,Jing J,Xie J,et al.Nuclear factor of activated T cells in cancer developme nt and treatment[J].Cancer Lett,2015,361(2):174-184.
[5].[5] Kraner SD,Norris CM.Astrocyte activation and the calcineurin/NFAT pathway in cerebrovascular disease[J].Front Aging Neurosci,2018,10:287.
[6].[6] Rowlands DJ,Islam MN,Das SR,et al.Activation of TNFR1 ectodomain shedding by mitochondrial Ca 2+ determines the severity of inflammation in mouse lung microvessels[J].J Clin Invest,2011,121(5):1986- 1999.
[7].[7] Liu J,Han Z,He Z.Mesenchymal stem cells suppress CaN/NFAT expression in the pulmonary arteries of rats with pulmonary hypertension[J].Exp Ther Med,2015,10(5):1657-1664.
[8].[8] Bierer R,Nitta CH,Friedman J,et al.NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal mice[J].Am J Physiol Lung Cell Mol Physiol, 2011,301(6):L872-880.
[9].[9] Kang K,Peng X,Zhang X,et al.MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells[J].J Biol Chem,2013,288(35):25414- 25427.
[10].[10] Balamurugan K.HIF-1 at the crossroads of hypoxia, inflammation, and cancer[J]. Int J Cancer,2016,138(5):1058- 1066.
[11].[11] Wu D,Potluri N,Lu J,et al.Structural integration in hypoxia-inducible factors[J].Nature,2015, 524(7565):303- 308.
[12].[12] Dyson HJ,Wright PE.Role of intrinsic protein disorder in the function and interactions of the transcriptional coactivators CREB-binding protein (CBP) and p300[J].J Biol Chem,2016, 291(13):6714- 6722.
[13].[13] Johns RA,Takimoto E,Meuchel LW,et al.Hypoxia-inducible factor 1α is a critical downstream mediator for hypoxia-induced mitogenic factor (FIZZ1/ RELMα)-induced pulmonary hypertension[J].Arterioscler Thromb Vasc Biol, 2015, 36(1):134-144.
[14].[14] Kojima H,Tokunou T,Takahara Y,et al.Hypoxia-inducible factor-1αdeletion in myeloid lineage attenuates hypoxia-induced pulmonary hypertension[J].Physiol Rep,2019,7(7):e14025.
[15].[15] Liu J,Wang W,Wang L,et al.IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1α and VEGF expression in vascul ar endothelial cells[J]. EBioMedicine,2018,33:196-210.
[16].[16] Cheng CC,Chi PL,Shen MC,et al.Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the inhibition of AKT/ERK-Dependent PDGF/HIF-1α in vitro and in vivo[J]. Int J Mol Sci,201 9,20(6):1468.
[17].[17] Kim MJ,Park SY,Chang HR,et al.Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2[J].BMB Rep,2017,50(6):308-317.
[18].[18] Harper RL,Maiolo S,Ward RJ,et al.BMPR2-expressing bone marrow-deriv ed endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo[J].Respirology, 2019,24(11):1095-1103.
[19].[19] Soon E,Crosby A,Southwood M,et al.Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2015,192(7):859- 872.
[20].[20] Tojais NF,Cao A,Lai YJ,et al.Codependence of bone morphogenetic protein receptor 2 and transforming growth factor-β in elastic fiber assembly a nd its perturbation in pulmonary arterial hypertension[J].Arterioscler Thromb Vasc Biol,2017,37(8):1559-1569.
[21].[21] Zhang Y,Peng B,Han Y.MiR-23a regulates the proliferation and migration of human pulmonary artery smooth muscle cells (HPASMCs) through targeting BMPR2/Smad1 signaling[J].Biomed Pharmacother,2018,103:1279-1286.
[22].[22] Pan P,Shen M,Yu H,et al.Advances in the development of Rho-associated protein kinase (ROCK) inhibitors[J].Drug Discov Today,2013,18(23-24):1323- 1333.
[23].[23] Liu J,Wada Y,Katsura M,et al.Rho-associated coiled-coil kinase (ROCK) in molecular regulation of angiogenesis[J].Theranostics,2018,8(21):6053-6069.
[24].[24] Kümper S,Mardakheh FK,Afshan MC,et al.Rho-associated kinase (ROCK) function is essential for cell cycle progression, senesce nce and tumorigenesis[J]. Elife,2016,5:e12994.
[25].[25] Guilluy C,Eddahibi S,Agard C,et al.RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling[J].Am J Respir Crit Care Med,2009,179(12):1151- 1158.
[26].[26] Csilla F,Chandran N,Diana Z,et al.Rho-kinase inhibition ameliorates dasatinib-induced endothelial dysfunction and pulmonary hypertension[J].Front Physiol,2018,9:537.
[27].[27] Wu F,Yao W,Yang J,et al.Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats[J].Biomed Pharmacother,2017,95:1161-1168.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(2):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(2):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(2):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(2):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[7]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(2):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[8]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(2):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[9]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(2):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
[10]刘雪鸢 徐燕萍 殷跃辉.交感神经去除术在肺动脉高压治疗中的研究进展[J].心血管病学进展,2020,(5):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]
LIU Xueyuan,XU Yanping,YIN Yuehui.Sympathetic Denervation in Treatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(2):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]